G-BA Approval received for OncoSil™ Device

News

G-BA Approval received for OncoSil™ Device

Sydney, Australia – 24 October 2024: Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce a significant milestone. Next step for fully reimbursed clinical trial approved by German Federal Joint Committee (G-BA) OncoSil is pleased to announce that it has been informed that the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) approved the Directive for testing the new treatment method: “Endoscopic injection-implantation of 32P-labeled microparticles in unresectable, locally advanced pancreatic tumors.” This decision establishes the legal foundation for a randomized controlled trial conducted under the framework of a Coverage with Evidence Development (CED) program, which allows for the treatment to be conditionally reimbursed while additional evidence is gathered to support its effectiveness. The trial is designed to demonstrate the patient-relevant benefits of this method compared to standard first-line chemotherapy.

This development marks a key step in advancing OncoSil’s innovative approach, which will significantly impact the treatment landscape for pancreatic cancer patients.